Partnering

Teva Pharmaceutical Industries has signed a license agreement with Alder BioPharmaceuticals, a Bothell, Washington-headquartered clinical-stage biopharmaceutical company, to develop, manufacture, and commercialize Alder’s investigational migraine drug, eptinezumab. The agreement resolves…

Pfizer and Berkeley Lights (BLI), an Emeryville, California-headquartered company developing platforms for biopharmaceutical processes, have signed an agreement to accelerate Pfizer’s monoclonal antibody (mAb) discovery and gene-editing workflows by using…

Roche has entered into a strategic, long-term partnership with GE Healthcare to jointly develop and co-market digital clinical-decision support software. The partnership will initially focus on products designed to accelerate…

Sanofi and Regeneron Pharmaceuticals, a Tarrytown, New York-based biopharmaceutical company, have agreed to expand their investment for the clinical development of cemiplimab, a programmed cell death protein 1 antibody for…

Otsuka Pharmaceutical and X-Chem, a Waltham, Massachusetts-headquartered biotechnology company, have signed a research agreement to advance the discovery process for new Otsuka drug compounds. Under the agreement, X-Chem will use…

Janssen Biotech, one of the pharmaceutical companies of Johnson & Johnson, has signed an agreement with Legend Biotech USA and Legend Biotech Ireland, subsidiaries of Genscript Biotech Corporation, a Hong…

Pfizer and Arvinas, a New Haven, Connecticut-headquartered biotechnology company focused on developing based on protein degradation, have signed an agreement worth up to $830 million for developing drug candidates using…

Bristol-Myers Squibb (BMS) and Taris Biomedical, a Lexington, Massachusetts-headquartered clinical-stage biopharmaceutical company, have entered into a clinical trial collaboration to evaluate the combination of Taris’ investigational product, TAR-200 (GemRIS), in…

Boehringer Ingelheim (BI) and Roche have signed a pact to focus on discovering and developing orally available locked nucleic acid oligonucleotides for treating inflammatory bowel diseases. Under the agreement, BI…

Pfizer Japan and Takeda Pharmaceutical Company plan to terminate co-promotion of Pfizer’s Xeljanz (tofacitinib citrate) 5-mg tablets, an oral Janus kinase inhibitor for treating rheumatoid arthritis, in Japan, effective March…